Duc-Vinh Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duc-Vinh Pham has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Pil-Hoon Park
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
6 shared publications Hoang-Anh Nguyen
Department of Pharmacology, Hanoi University of Pharmacy, Hanoi, Vietnam
4 shared publicationsThuy-Duong Nguyen
Department of Pharmacology, Hanoi University of Pharmacy, Hanoi, Vietnam
4 shared publicationsHong-Linh Tran
Department of Pharmacology, Hanoi University of Pharmacy, Hanoi, Vietnam
3 shared publications- Jae-Hoon Chang
College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea
3 shared publications Van Thi-Hong Tran
Department of Pharmacology and Biochemistry, Vietnam National Institute of Medicinal Materials, Hanoi, Vietnam
3 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (41) , 49144-49157
Bioactive compounds from Beilschmiedia percoriacea leaves: isolation, structural characterization, and biological evaluations
Two new sesquiterpenes and twelve known isolates from Beilschmiedia percoriacea displayed potent anti-inflammatory, antidiabetic, and antioxidant activities.
- 16 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (41) , 49144-49157
Open AccessBioactive compounds from Beilschmiedia percoriacea leaves: isolation, structural characterization, and biological evaluations
Two new sesquiterpenes and twelve known isolates from Beilschmiedia percoriacea displayed potent anti-inflammatory, antidiabetic, and antioxidant activities.
- Open Access
- 12 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Binary mineral nanoparticles enable intravascular delivery of metal ions to tumors for metalloimmunotherapy
Although disruptions in metal ion homeostasis leading to severe cellular damage and regulated cell death are a promising strategy for cancer immunotherapy, challenges in overloading these ions to tumor cells without premature release have limited their therapeutic applications. In this study, we develop binary mineral nanoparticles incorporating both Ca2+ and Na+ ions to enhance the cytotoxic effects of ion interference in cancer immunotherapy. Engineered using a microfluidic system for uniform size distribution and scalability, these nanoparticles exhibit pH-sensitive ion release. Systemically administered, they preferentially accumulate in tumors, elevating intracellular Ca2+ and Na+ levels and inducing immunogenic cell death without calcium channel activators or other small-molecule inducers. Our binary mineral nanoparticles significantly enhance antitumor immunity, especially when combined with an immune checkpoint inhibitor, leading to long-term immunity and inhibition of metastasis. This nanotechnology-enabled synergistic delivery of Ca²⁺ and Na⁺ ions represents a promising adjunct to existing metalloimmunotherapy strategies for cancer eradication.
- 12 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBinary mineral nanoparticles enable intravascular delivery of metal ions to tumors for metalloimmunotherapy
Although disruptions in metal ion homeostasis leading to severe cellular damage and regulated cell death are a promising strategy for cancer immunotherapy, challenges in overloading these ions to tumor cells without premature release have limited their therapeutic applications. In this study, we develop binary mineral nanoparticles incorporating both Ca2+ and Na+ ions to enhance the cytotoxic effects of ion interference in cancer immunotherapy. Engineered using a microfluidic system for uniform size distribution and scalability, these nanoparticles exhibit pH-sensitive ion release. Systemically administered, they preferentially accumulate in tumors, elevating intracellular Ca2+ and Na+ levels and inducing immunogenic cell death without calcium channel activators or other small-molecule inducers. Our binary mineral nanoparticles significantly enhance antitumor immunity, especially when combined with an immune checkpoint inhibitor, leading to long-term immunity and inhibition of metastasis. This nanotechnology-enabled synergistic delivery of Ca²⁺ and Na⁺ ions represents a promising adjunct to existing metalloimmunotherapy strategies for cancer eradication.
- Open Access
- 8 January 2026
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
- Vol. 27
Garlic extract (Allium Sativum L.) mitigates oleic acid-induced lipid accumulation and lipotoxicity in hepatocytes
Garlic extract has long been used in traditional medicine for managing liver disorders; however, its effects on hepatic steatogenesis remain unexplored. The study was conducted to evaluate the inhibitory effect on lipid accumulation of garlic extract in oleic acid-induced HepG2 hepatocytes. Pretreatment with GE at 30 μg/mL significantly abrogated the steatogenic effects of OA. Specifically, GE reduced the intracellular lipid accumulation, as evidenced by both Oil Red O staining and BODIPY fluorescence assays. Additionally, GE exerted dose-dependent inhibitory effects on OA-induced increases in cellular triglyceride levels. Garlic extract at 10 and 30 μg/mL exhibited strong antioxidant effects by reducing the formation of reactive oxygen species (ROS) and malondialdehyde (MDA) in oleic acid-induced HepG2 hepatocytes. Garlic extract at 30 μg/mL also protected hepatocytes from OA-induced damage, as evidenced by the restoration of cell viability, reductions in AST and ALT activity, and inhibition of apoptotic cell death through decreased expression of caspase-3. Taken together, the results indicated that garlic extract may have potential for managing hepatic steatosis
- 8 January 2026
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
- Vol. 27
Open AccessGarlic extract (Allium Sativum L.) mitigates oleic acid-induced lipid accumulation and lipotoxicity in hepatocytes
Garlic extract has long been used in traditional medicine for managing liver disorders; however, its effects on hepatic steatogenesis remain unexplored. The study was conducted to evaluate the inhibitory effect on lipid accumulation of garlic extract in oleic acid-induced HepG2 hepatocytes. Pretreatment with GE at 30 μg/mL significantly abrogated the steatogenic effects of OA. Specifically, GE reduced the intracellular lipid accumulation, as evidenced by both Oil Red O staining and BODIPY fluorescence assays. Additionally, GE exerted dose-dependent inhibitory effects on OA-induced increases in cellular triglyceride levels. Garlic extract at 10 and 30 μg/mL exhibited strong antioxidant effects by reducing the formation of reactive oxygen species (ROS) and malondialdehyde (MDA) in oleic acid-induced HepG2 hepatocytes. Garlic extract at 30 μg/mL also protected hepatocytes from OA-induced damage, as evidenced by the restoration of cell viability, reductions in AST and ALT activity, and inhibition of apoptotic cell death through decreased expression of caspase-3. Taken together, the results indicated that garlic extract may have potential for managing hepatic steatosis
- 3 December 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (1) , 130-148
Gnetum Montanum Markgr. Extract mitigates gouty arthritis by targeting urate crystal-induced NLRP3 inflammasome activation
Gouty arthritis is a common metabolic disorder characterized by the deposition of monosodium urate (MSU) crystals in joints. Aberrant activation of the NLRP3 inflammasome is a key driver of MSU-induced joint inflammation, making it a promising therapeutic target for gouty arthritis. Gnetum montanum Markgr. has long been used in traditional medicine in parts of Asia to treat gout; however, its effects on gout-specific inflammatory responses have not been fully elucidated. In this study, we used two cell models, including MSU-stimulated mouse primary peritoneal and THP1 derived macrophages, in combination with western blot analysis, enzymatic activity assays, ELISA method, and flow cytometry analysis to evaluate the protective effect of G. montanum extract (GME) against MSU-driven inflammation. A mouse model of MSU-induced paw edema was then employed to validate the in vivo anti-inflammatory efficacy. We found that GME alleviated gouty inflammation by inhibiting NLRP3 inflammasome activation in mouse peritoneal and human THP-1 macrophages. GME also protected macrophages from MSU-induced pyroptosis, a pro-inflammatory form of programmed cell death. Mechanistically, GME suppressed xanthine oxidase (XO) activation triggered by MSU crystals, resulting in decreased reactive oxygen species (ROS) production. This reduction in ROS prevented the upregulation of thioredoxin-interacting protein (TXNIP), a key mediator that binds to and activates NLRP3. Furthermore, oral administration of GME in mice attenuated MSU-induced paw inflammation, likely through downregulation of XO-driven oxidative stress and NLRP3 inflammasome signaling. These findings suggest that GME effectively modulates gout-specific inflammatory pathways and warrants further investigation of GME as a potential therapeutic candidate for gouty arthritis. Graphical abstract
- 3 December 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (1) , 130-148
Gnetum Montanum Markgr. Extract mitigates gouty arthritis by targeting urate crystal-induced NLRP3 inflammasome activation
Gouty arthritis is a common metabolic disorder characterized by the deposition of monosodium urate (MSU) crystals in joints. Aberrant activation of the NLRP3 inflammasome is a key driver of MSU-induced joint inflammation, making it a promising therapeutic target for gouty arthritis. Gnetum montanum Markgr. has long been used in traditional medicine in parts of Asia to treat gout; however, its effects on gout-specific inflammatory responses have not been fully elucidated. In this study, we used two cell models, including MSU-stimulated mouse primary peritoneal and THP1 derived macrophages, in combination with western blot analysis, enzymatic activity assays, ELISA method, and flow cytometry analysis to evaluate the protective effect of G. montanum extract (GME) against MSU-driven inflammation. A mouse model of MSU-induced paw edema was then employed to validate the in vivo anti-inflammatory efficacy. We found that GME alleviated gouty inflammation by inhibiting NLRP3 inflammasome activation in mouse peritoneal and human THP-1 macrophages. GME also protected macrophages from MSU-induced pyroptosis, a pro-inflammatory form of programmed cell death. Mechanistically, GME suppressed xanthine oxidase (XO) activation triggered by MSU crystals, resulting in decreased reactive oxygen species (ROS) production. This reduction in ROS prevented the upregulation of thioredoxin-interacting protein (TXNIP), a key mediator that binds to and activates NLRP3. Furthermore, oral administration of GME in mice attenuated MSU-induced paw inflammation, likely through downregulation of XO-driven oxidative stress and NLRP3 inflammasome signaling. These findings suggest that GME effectively modulates gout-specific inflammatory pathways and warrants further investigation of GME as a potential therapeutic candidate for gouty arthritis. Graphical abstract
- Open Access
- 25 March 2025
- Published by Wolters Kluwer Health in Asian Pacific Journal of Tropical Biomedicine
- Vol. 15 (3) , 98-108
Gnetum montanum extract ameliorates ethanol-induced hepatic injury and metabolic dysfunction via inhibition of xanthine oxidase
Objective: To investigate the effects of a crude extract from Gnetum montanum Markgr. on ethanol-induced hepatotoxicity and metabolic disorders. Methods: Alcoholic liver disorder was induced in mice by administering increasing doses of ethanol via oral gavage. Biomarkers of liver injury and oxidative stress were assessed at the end of the study. Liver tissue damage and fat deposition were evaluated using hematoxylin and eosin and oil red O staining, respectively. In addition, key biomarkers were examined in acetaldehyde-treated HepG2 cells. Results: Ethanol consumption induced characteristic pathological changes, including elevated serum markers of liver injury, hepatic lipid accumulation, and oxidative stress in liver tissues. Oral administration of Gnetum montanum extract (175 and 350 mg/kg) decreased serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, and bilirubin levels in ethanol-treated mice. The extract also lowered triglyceride levels in serum and liver tissue in a dose-dependent manner. Furthermore, it mitigated malondialdehyde levels, preserved reduced glutathione levels, and enhanced catalase activity and total antioxidant capacity in liver tissue homogenates. Additionally, ethanol-induced hyperuricemia was suppressed by Gnetum montanum extract by inhibiting xanthine oxidase activity. Similar effects were observed in Gnetum montanum extract-treated HepG2 cells. Conclusions: This study demonstrates that Gnetum montanum extract alleviates ethanol-induced hepatic injury by alleviating oxidative stress and inhibiting xanthine oxidase activity.
- 25 March 2025
- Published by Wolters Kluwer Health in Asian Pacific Journal of Tropical Biomedicine
- Vol. 15 (3) , 98-108
Open AccessGnetum montanum extract ameliorates ethanol-induced hepatic injury and metabolic dysfunction via inhibition of xanthine oxidase
Objective: To investigate the effects of a crude extract from Gnetum montanum Markgr. on ethanol-induced hepatotoxicity and metabolic disorders. Methods: Alcoholic liver disorder was induced in mice by administering increasing doses of ethanol via oral gavage. Biomarkers of liver injury and oxidative stress were assessed at the end of the study. Liver tissue damage and fat deposition were evaluated using hematoxylin and eosin and oil red O staining, respectively. In addition, key biomarkers were examined in acetaldehyde-treated HepG2 cells. Results: Ethanol consumption induced characteristic pathological changes, including elevated serum markers of liver injury, hepatic lipid accumulation, and oxidative stress in liver tissues. Oral administration of Gnetum montanum extract (175 and 350 mg/kg) decreased serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, and bilirubin levels in ethanol-treated mice. The extract also lowered triglyceride levels in serum and liver tissue in a dose-dependent manner. Furthermore, it mitigated malondialdehyde levels, preserved reduced glutathione levels, and enhanced catalase activity and total antioxidant capacity in liver tissue homogenates. Additionally, ethanol-induced hyperuricemia was suppressed by Gnetum montanum extract by inhibiting xanthine oxidase activity. Similar effects were observed in Gnetum montanum extract-treated HepG2 cells. Conclusions: This study demonstrates that Gnetum montanum extract alleviates ethanol-induced hepatic injury by alleviating oxidative stress and inhibiting xanthine oxidase activity.
- Open Access
- 13 March 2025
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
- Vol. 22
A valproic acid-induced cell model of hepatic steatosis: Effects of Gnetum montanum extract
Hepatic steatosis is a multifactorial disorder with no specific pharmacological treatment available. Gnetum montanum has been traditionally used to treat metabolic disorders; however, its effects on hepatic steatogenesis remain unexplored. This study aimed to establish a method for inducing steatosis in hepatocytes and to investigate whether G. montanum extract (GME) exerts beneficial effects on hepatocellular lipid metabolism. We found that valproic acid (VPA) at a concentration of 3 mM effectively induced extensive lipid accumulation in HepG2 human hepatoma cells, as evidenced by the formation of intracellular lipid droplets and an increase in cellular triglyceride and cholesterol levels, with minimal effects on cell viability after 48 hours of incubation. Interestingly, pretreatment with GME significantly abrogated the steatogenic effects of VPA. Specifically, GME reduced the intracellular neutral lipid pool, as determined by Oil Red O staining. Fluorescent assays using BODIPY 493/503 in combination with imaging techniques and flow cytometry further confirmed that GME decreased both the number of lipid droplets and the accumulation of neutral lipids in VPA-treated HepG2 cells. Additionally, GME exerted dose-dependent inhibitory effects on VPA-induced increases in cellular triglyceride and total cholesterol levels. Taken together, this study has established a cell model for evaluating in vitro anti-hepatic steatotic activity and suggests G. montanum as a promising medicinal plant for managing hepatic steatosis. Keywords: Gnetum montanum, Hepatic steatosis, Lipid droplets, NALFD, Valproate.
- 13 March 2025
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
- Vol. 22
Open AccessA valproic acid-induced cell model of hepatic steatosis: Effects of Gnetum montanum extract
Hepatic steatosis is a multifactorial disorder with no specific pharmacological treatment available. Gnetum montanum has been traditionally used to treat metabolic disorders; however, its effects on hepatic steatogenesis remain unexplored. This study aimed to establish a method for inducing steatosis in hepatocytes and to investigate whether G. montanum extract (GME) exerts beneficial effects on hepatocellular lipid metabolism. We found that valproic acid (VPA) at a concentration of 3 mM effectively induced extensive lipid accumulation in HepG2 human hepatoma cells, as evidenced by the formation of intracellular lipid droplets and an increase in cellular triglyceride and cholesterol levels, with minimal effects on cell viability after 48 hours of incubation. Interestingly, pretreatment with GME significantly abrogated the steatogenic effects of VPA. Specifically, GME reduced the intracellular neutral lipid pool, as determined by Oil Red O staining. Fluorescent assays using BODIPY 493/503 in combination with imaging techniques and flow cytometry further confirmed that GME decreased both the number of lipid droplets and the accumulation of neutral lipids in VPA-treated HepG2 cells. Additionally, GME exerted dose-dependent inhibitory effects on VPA-induced increases in cellular triglyceride and total cholesterol levels. Taken together, this study has established a cell model for evaluating in vitro anti-hepatic steatotic activity and suggests G. montanum as a promising medicinal plant for managing hepatic steatosis. Keywords: Gnetum montanum, Hepatic steatosis, Lipid droplets, NALFD, Valproate.
- 17 August 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 229, 116496
NLRP3 inflammasome activation contributes to the development of the pro-fibrotic phenotype of lung fibroblasts
- 17 August 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 229, 116496
NLRP3 inflammasome activation contributes to the development of the pro-fibrotic phenotype of lung fibroblasts
- 25 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 330, 118226
Mimosa pudica L. extract ameliorates pulmonary fibrosis via modulation of MAPK signaling pathways and FOXO3 stabilization
- 25 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 330, 118226
Mimosa pudica L. extract ameliorates pulmonary fibrosis via modulation of MAPK signaling pathways and FOXO3 stabilization
- 20 February 2024
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
Synergistic effect of Erythrina variegata L. and tamoxifen against the growth of breast cancer cells
Breast cancer is the most common malignancy and the second leading cause of death in women. While tamoxifen (TAM) remains to be a first-line agent for prevention and treatment of estrogen-receptor (ER) positive breast tumors, TAM resistance represents one of the biggest clinical challenges in breast cancer therapy. Therefore, there has been growing interest in the identification of novel agents including those of plant origin that enhance the TAM sensitivity of breast cancer cells. In the present study, we aimed to evaluate the synergistic effect of Erythrina variegata extract (EVE) and TAM on the suppression of breast cancer cell growth using MCF-7 cell model and conventional bioassays such as MTT and colony formation assay, cell cycle analysis, and immunocytochemistry. Interestingly, MTT assay in combination with Chou-Talalay analysis demonstrated the potent synergism between EVE and tamoxifen against MCF-7 cell survival. Additionally, co-treatment of MCF-7 cells with EVE and TAM more significantly suppressed colony formation, cell cycle progression, and the nuclear expression of proliferative marker Ki67 compared to TAM alone. These findings imply that EVE potentiates the anti-proliferative effect of TAM in MCF-7 breast cancer cells and may become a promising agent in the treatment of ER positive breast cancer.
- 20 February 2024
- Published by Hanoi University of Pharmacy in Tạp chí Nghiên cứu Dược và Thông tin Thuốc
Synergistic effect of Erythrina variegata L. and tamoxifen against the growth of breast cancer cells
Breast cancer is the most common malignancy and the second leading cause of death in women. While tamoxifen (TAM) remains to be a first-line agent for prevention and treatment of estrogen-receptor (ER) positive breast tumors, TAM resistance represents one of the biggest clinical challenges in breast cancer therapy. Therefore, there has been growing interest in the identification of novel agents including those of plant origin that enhance the TAM sensitivity of breast cancer cells. In the present study, we aimed to evaluate the synergistic effect of Erythrina variegata extract (EVE) and TAM on the suppression of breast cancer cell growth using MCF-7 cell model and conventional bioassays such as MTT and colony formation assay, cell cycle analysis, and immunocytochemistry. Interestingly, MTT assay in combination with Chou-Talalay analysis demonstrated the potent synergism between EVE and tamoxifen against MCF-7 cell survival. Additionally, co-treatment of MCF-7 cells with EVE and TAM more significantly suppressed colony formation, cell cycle progression, and the nuclear expression of proliferative marker Ki67 compared to TAM alone. These findings imply that EVE potentiates the anti-proliferative effect of TAM in MCF-7 breast cancer cells and may become a promising agent in the treatment of ER positive breast cancer.
- Open Access
- 28 October 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (1) , 273-291
Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal cells via glycolytic reprogramming
- 28 October 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (1) , 273-291
Open AccessAdiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal cells via glycolytic reprogramming